Encapsulation of an 86-kDa Assembly Intermediate inside the Cavities of GroEL and Its Single-ring Variant SR1 by GroES*

Jiu-Li Song, Jun Li, Yi-Shuian HuangDagger, and David T. Chuang§

From the Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390

Received for publication, September 21, 2002, and in revised form, October 21, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We described previously that during the assembly of the alpha 2beta 2 heterotetramer of human mitochondrial branched-chain alpha -ketoacid dehydrogenase (BCKD), chaperonins GroEL/GroES interact with the kinetically trapped heterodimeric (alpha beta ) intermediate to facilitate conversion of the latter to the native BCKD heterotetramer. Here, we show that the 86-kDa heterodimeric intermediate possesses a native-like conformation as judged by its binding to a fluorescent probe 1-anilino-8-naphthalenesulfonate. This large heterodimeric intermediate is accommodated as an entity inside cavities of GroEL and its single-ring variant SR1 and is encapsulated by GroES as indicated by the resistance of the heterodimer to tryptic digestion. The SR1-alpha beta -GroES complex is isolated as a stable single species by gel filtration in the presence of Mg-ATP. In contrast, an unfolded BCKD fusion protein of similar size, which also resides in the GroEL or SR1 cavity, is too large to be capped by GroES. The cis-capping mechanism is consistent with the high level of BCKD activity recovered with the GroEL-alpha beta complex, GroES, and Mg-ATP. The 86-kDa native-like heterodimeric intermediate in the BCKD assembly pathway represents the largest protein substrate known to fit inside the GroEL cis cavity underneath GroES, which significantly exceeds the current size limit of 57 kDa established for unfolded proteins.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Chaperonins GroEL/GroES, which are homologues of mitochondrial Hsp60/10, respectively, have been shown to promote proper folding and assembly of a variety of proteins (for review see Refs. 1 and 2). GroEL is a double-ring complex with two heptameric rings, consisting of identical 57-kDa subunits, which are stacked back to back. The efficient folding for most proteins has been shown to occur inside the cavity of the cis ring that houses the unfolded or partially folded protein, following encapsulation or capping of the cis ring by dome-shaped heptameric GroES in the presence of Mg-ATP (3). The subsequent binding of Mg-ATP to the unoccupied or trans ring of GroEL results in the collapse of the cis ring assembly with the concomitant release of GroES and partially or completely folded protein from the cis cavity. It has been generally accepted that only proteins of 55-57 kDa or smaller in size can fit inside the cavity encapsulated by GroES, as shown by in vivo (4, 5) and in vitro (6) studies. For certain proteins larger than this size, for example, 75-kDa methylmalonyl-CoA mutase (3) and 72-kDa phage P22 tailspike protein (7) that are capable of binding to GroEL, chaperonin-assisted folding is independent of GroES. It was shown recently, however, that both chaperonins GroEL/GroES are required for the productive folding of an 86-kDa maltose-binding protein fusion (8) and 82-kDa mitochondrial aconitase (9). Interestingly, for this group of large proteins, productive folding is achieved through binding of GroES to the trans ring of GroEL. GroEL was also shown to trap heat-induced inactive 98-kDa citrate synthase homodimers (10) and thermally induced partially active 66-kDa rhodanese dimers (11). In the presence of GroES and Mg-ATP, the trapped dimers of citrate synthase or rhodanese are released from GroEL in the monomeric form. It is not clear whether GroES binds in cis or in trans to the complex formed between GroEL and these relatively large folded intermediates.

Our laboratory is interested in the potential role of chaperonins in promoting the assembly of mitochondrial macromolecular multi-enzyme complexes. We have shown that chaperonins GroEL/GroES are indispensable for both folding and assembly of the alpha 2beta 2 heterotetramer of branched-chain alpha -ketoacid dehydrogenase (BCKD),1 a component of the 4 × 106-Da human mitochondrial BCKD complex, both in Escherichia coli (12) and in vitro (13). GroEL binds to an ensemble of 86-kDa alpha beta heterodimeric intermediates, which are kinetically trapped during assembly, to produce a stable GroEL-alpha beta complex. In the presence of GroES and Mg-ATP, the heterodimeric intermediate undergoes multiple rounds of dissociation and reassociation to facilitate the conversion of the heterodimeric intermediate to the native BCKD heterotetramer (14, 15). Our data have established the central role of chaperonin GroEL/GroES in promoting oligomeric protein assembly through iterative annealing of non-productive assembly intermediate.

Because of the large size associated with the alpha beta assembly intermediate of BCKD, a question arises as to whether the productive folding of the GroEL-alpha beta complex proceeds through the cis or trans capping of the GroEL cavity by GroES. We have shown previously that the GroEL-alpha beta complex is resistant to protease digestion in the presence of GroES and Mg-ADP, suggesting the enclosure of the 86-kDa heterodimer inside the GroEL cis cavity by GroES (15). However, the interpretation of these data was complicated by the presence of the trans ring in GroEL. In the present study, we revisited this issue by investigating the encapsulation of the heterodimer inside GroEL along with its single-ring variant SR1. We showed that the 86-kDa heterodimeric intermediate inside the cavities of both GroEL and SR1 was encapsulated by GroES. In contrast, an unfolded fusion protein of similar size, which also resides in the GroEL or SR1 cavity, is too large to be capped by GroES. The 86-kDa heterodimeric intermediate represents the largest protein substrate ever known to fit inside the GroEL cis cavity underneath GroES. This finding indicates that for assembly intermediates with compact native-like conformations, the size limit for cis folding is significantly larger than 57 kDa established for unfolded proteins (4-6).

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Bacterial chaperonins GroEL/GroES and recombinant human BCKD were prepared as described previously (13). 1-Anilino-8-naphthalenesulfonate (ANS), trypsin (type III, from bovine pancreas), trypsin-chymotrypsin inhibitor (from soybean), Reactive Red 120-agarose (type 3000-CL), and alpha -lactalbumin (type III, calcium-depleted, from bovine milk) were obtained from Sigma. Bovine lactoferrin was purchased from ICN Biochemicals, Inc. (Aurora, OH). A pET vector for the expression of single-ring GroEL variant SR1 was a generous gift from Dr. Arthur Horwich.

Expression and Purification of SR1-- The expression plasmid for SR1 was transformed into BL21 (DE3) cells. Cells were grown in the LB medium containing 100 µg/ml ampicillin at 37 °C overnight, and expression for SR1 was induced with 1 mM isopropyl-beta -D-thiogalactopyranoside for 3 h at 37 °C. The SR1 protein was purified at 4 °C using a previously described protocol with modifications (16). Briefly, cells from 4-liter culture were collected and re-suspended in 150 ml of buffer containing 20 mM Tris, pH 7.4, 50 mM KCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and 0.4 mg/ml lysozyme. After cells were broken by sonication, the lysate was fractionated by centrifugation in a Ti60 rotor at 120,000 × g for 35 min at 4 °C. The supernatant was applied to a Q-Sepharose Fast-Flow column (Amersham Biosciences), and proteins were eluted with a gradient of 0 to 1 M NaCl in Buffer A (50 mM Tris, pH 7.4, 1 mM EDTA, 0.5 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride). SR1-containing fractions were collected, and protein was precipitated with 65% ammonium sulfate. Following centrifugation, the protein pellet was dissolved in Buffer A, and solubilized proteins were fractionated on an FPLC Superdex 200 gel filtration column equilibrated in the same buffer. At this stage, the SR1 protein was >98% pure as judged by SDS-PAGE. To remove minor contaminants, it was dialyzed against 20 mM Tris, pH 7.4, and 5 mM MgCl2 and purified further on a Reactive Red 120-Agarose (type 3000-CL) dye column equilibrated in the same buffer (17).

Engineering and Expression of BCKD alpha -11-beta Fusion Protein-- For the construction of an expression plasmid for the alpha -11-beta fusion, three fragments from the pHisT-E1 vector (18) were produced: a 45-bp NcoI/XhoI fragment containing the His6 tag and the tobacco etch-virus protease cleavage site, a 751-bp XhoI/SmaI fragment encoding a 5' portion of the alpha  subunit, and a 1202-bp PstI/EcoRI fragment encoding a C-terminal segment of the beta  subunit. The linker region of 11 amino acids (GSEALEAAERS) between the alpha  and beta  subunit was derived from the sequence connecting the alpha  and beta  domains of tryptophan synthase (19). The nucleotide sequence encoding this linker was 5'-GGATCCGAAGCATTAGAAGCCGCTGAGAGATCT-3', which contained a BamHI site at the 5' end and a BglII site at the 3' terminus. The BCKD-alpha cDNA with the linker immediately downstream of the 3' cDNA end was amplified, followed by digestion of the PCR product to produce a SmaI/BamHI fragment. The BCKD-beta cDNA with the linker attached to the 5' cDNA end was also amplified, and digestion of this PCR product resulted in a PstI/BamHI fragment. The SmaI/BamHI and PstI/BamHI fragments, along with the above three fragments derived from the pHisT-E1 plasmid, were ligated into the pTrcHisB expression vector (Invitrogen) pre-digested with NcoI and EcoRI. The resultant plasmid pHisT-alpha -11-beta and the pGroESL plasmid overexpressing GroEL and GroES (12) were co-transformed into BL21 cells. Transformed cells were grown in the LB medium at 37 °C until A600 nm at 0.75 was reached. Expression of the BCKD fusion protein was induced with 1 mM isopropyl-beta -D-thiogalactopyranoside, followed by an overnight growth at 37 °C. The His6-tagged BCKD alpha -11-beta fusion protein was isolated from the cell lysate with nickel-nitrilotriacetic acid-agarose as described previously (18).

Preparation of GroEL-Protein and SR1-Protein Complexes-- KSCN-induced alpha beta heterodimers were produced by incubating His6-tagged BCKD (11.5 µM, alpha 2beta 2 heterotetramer) with 400 mM KSCN in Buffer B (50 mM potassium phosphate, pH 7.5, 250 mM KCl) containing 2 mM dithiothreitol for 45 min at 23 °C (14). The incubation mixture was diluted 2-fold into Buffer B containing 8 µM GroEL or SR1. Following incubation for 4 h at 23 °C, the complex formed was purified on an FPLC Superdex 200 gel filtration column. Fractions containing the GroEL-alpha beta or the SR1-alpha beta complex were collected and concentrated in a Millipore (Bedford, MA) Ultrafree-15 filter device with a 30-kDa cut-off membrane.

GroEL-alpha -11-beta and SR1-alpha -11-beta complexes were prepared by diluting the 8 M urea-denatured alpha -11-beta fusion protein into Buffer C (50 mM potassium phosphate, pH 7.5, 100 mM KCl) containing GroEL or SR1 on ice. The mixture was kept at 4 °C overnight, concentrated, and purified on an FPLC Superdex 200 column as described above.

Limited Digestion of Chaperonin-Protein Complex with Trypsin-- GroEL-protein and SR1-protein complexes at 0.8 µg/µl in Buffer C with or without 0.67 µg/µl GroES, 13 mM Mg-ADP, or Mg-ATP were subjected to limited digestion with 20 µg/ml trypsin at 23 °C for 10 min. The reaction was terminated by adding trypsin-chymotrypsin inhibitor to a final concentration of 27 µg/ml. Samples were analyzed by SDS-PAGE and Western blotting using a combination of anti-alpha subunit and anti-beta subunit antibodies as a probe.

Fluorescence Assays of BCKD and BCKD Fusion Proteins with ANS-- The urea-denatured alpha -11-beta fusion protein was generated by incubation with 8 M urea at 23 °C for 1 h. Native BCKD, the KSCN-induced heterodimer, or the urea-denatured alpha -11-beta fusion protein at 0.1 mg/ml was mixed with 50 µM ANS in Buffer C. Emission spectra were recorded from 400 to 550 nm with the excitation wavelength at 365 nm on a PerkinElmer Life Sciences luminescence spectrometer LS 50B. Each spectrum was an average of three consecutive scans and was corrected for contributions from the buffer solution.

Co-purification of GroES with SR1-alpha beta or SR1-beta Complexes by HPLC and Quantification of Protein Components by Densitometry-- The SR1-beta complex was prepared as described previously except that SR1 was used instead of GroEL (13). The SR1-alpha beta or SR1-beta complex (60 µg) was incubated with 100 µg of GroES in Buffer C containing 5 mM Mg-ATP for 5 min at 23 °C. The mixture was fractionated on an HPLC G3000SWXL gel filtration column in the same buffer containing 0.1 mM Mg-ATP. As a control, the SR1-beta complex was incubated with GroES in the absence of Mg-ATP and separated on HPLC with Mg-ATP omitted from the column buffer. 5 min after the sample injection, fractions were collected every 20 s and analyzed by SDS-PAGE. To determine the stoichiometry of protein components in the SR1-alpha beta -GroES or the SR1-beta -GroES complex, different amounts of SR1, BCKD, or GroES were run on the same gel. After staining with Coomassie Blue, gels were scanned on a Molecular Dynamics densitometer (model 300A) and analyzed by ImageQuant. Standard curves for SR1, BCKD, and GroES were generated by plotting the known amount of the protein against the intensity of the band on the same gel. The amount of each protein component in the SR1-alpha beta (or -beta )-GroES complex was calculated using the standard curve for each protein.

GroEL/GroES-mediated Recovery of BCKD Activity-- The renaturation of urea-denatured BCKD and alpha -11-beta fusion protein was carried out as described previously (13). BCKD activity was also recovered by incubating 0.8 µM of the GroEL-alpha beta or the GroEL-alpha -11-beta complex with 2 µM GroES and 10 mM Mg-ATP as described previously (14).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression and Characterization of Large Target Proteins-- The His6-tagged alpha beta heterodimeric intermediate in the BCKD assembly pathway was produced by incubating the N-terminally His6-tagged BCKD alpha 2beta 2 heterotetramer in 400 mM KSCN for 45 min at 23 °C, followed by a 2-fold dilution. The size of the resultant alpha beta heterodimer was 86 kDa, as determined by FPLC gel filtration and dynamic light scattering in the presence of 200 mM KSCN (14). A second target protein, the His6-tagged alpha -11-beta fusion, was generated by fusing the N-terminally His6-tagged alpha  subunit to the beta  subunit through an 11-residue linker derived from E. coli tryptophan synthase (19). The alpha -11-beta fusion migrated as a 170-kDa species in FPLC gel filtration, similar to the size of wild-type BCKD heterotetramer. The alpha -11-beta fusion shows Km values of 0.5 µM for thiamin pyrophosphate and 62 µM for substrate alpha -ketoisovalerate, essentially indistinguishable from those obtained with the wild-type BCKD (Table I). The kcat value for the alpha -11-beta fusion is 4.0 s-1, which is approximately one-half that obtained with the wild-type BCKD. The size of the 8 M urea-denatured alpha -11-beta fusion was determined by sedimentation equilibrium centrifugation (data not shown). The data were fitted to a single species model with a size of 86,671 Da for the unfolded alpha -11-beta fusion polypeptide. The above data, taken together, indicate that the native alpha -11-beta exists as a homodimeric protein.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Kinetic constants for wild-type alpha 2beta 2 and alpha -11-beta fusion BCKD

Conformations of the target proteins were characterized by fluorometry using the ANS as a hydrophobic probe. Native and urea-denatured proteins were incubated with 50 µM ANS. The reaction mixtures were excited at 365 nm, and fluorescence emission measured as a function of wavelength (Fig. 1). ANS bound to the alpha beta assembly intermediate or the alpha 2beta 2 native BCKD exhibits similar spectra with a maximum at 473 nm. The data indicate that the heterodimeric assembly intermediate possesses a folded structure similar to native BCKD. In contrast, the urea-denatured alpha -11-beta fusion with the unfolded conformation fail to bind to ANS, as indicated by the absence of fluorescence emission after subtracting emission from the unbound ANS.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Fluorescence emission spectra of ANS-bound wild-type BCKD (alpha 2beta 2), its heterodimeric intermediate (alpha beta ), and urea-denatured alpha -11-beta fusion. ANS (50 µM) were mixed with wild-type His6-tagged BCKD (alpha 2beta 2) in Buffer C, KSCN-induced heterodimeric intermediate (alpha beta ) in 200 mM KSCN, or urea-denatured alpha -11-beta fusion in 8 M urea (see "Experimental Procedures"). Following a 5-min incubation at 23 °C, the emission spectrum was recorded at the excitation wavelength of 365 nm. Each spectrum was an average of three consecutive scans and was corrected for contributions from the buffer solution.

Capping of the 86-kDa Native-like Heterodimeric Intermediate inside GroEL and SR1 Cavities by GroES-- Double-ring GroEL or its single-ring variant SR1 was incubated with a molar excess of KSCN-induced alpha beta heterodimer; the resultant GroEL-alpha beta and SR1-alpha beta complexes were purified by FPLC gel filtration. Identical amounts of the GroEL-alpha beta or the SR1-alpha beta complex were incubated with GroES and trypsin in the presence or absence of nucleotides for 10 min at 23 °C. Digestion mixtures were analyzed by SDS-PAGE (upper panel) and Western blotting (lower panel) (Fig. 2). In the absence of GroES and nucleotide, the alpha beta heterodimer bound to GroEL was digested completely after incubation of the complex with trypsin (Fig. 2, both panels, lane 2). The heterodimer was also digested when GroES alone (lane 3), or GroES and Mg-ATP (lane 5) were added to the GroEL-alpha beta complex (Fig. 2, both panels). Under these conditions, GroES was unable to form a stable complex with GroEL, resulting in the degradation of the alpha beta heterodimer by the protease. The smaller bands under GroEL, which are stained with Coomassie Blue (upper panel), do not represent the undigested alpha beta heterodimer, as indicated by the absence of cross-reacting materials in Western blotting with the combined anti-alpha and anti-beta antibodies as probes (Fig. 2, lower panel, lanes 3 and 5). These smaller bands, which migrate slower than GroES, are proteolytic products of GroEL. In the presence of Mg-ADP and GroES (lane 4), a significant portion of the heterodimer bound to GroEL was protected from tryptic digestion (Fig. 2, both panels). The amounts of alpha  and beta  subunits resistant to trypsin digestion were 56.3 and 39.7%, respectively, of the starting material (lane 1) as determined by densitometry of the Western blot (Fig. 2, lower panel). The data are explained by the fact that GroES binds equally to either the cis or the trans ring of GroEL, resulting in approximately half of the cis cavity being capped by GroES. Only the alpha beta heterodimer inside the GroES-enclosed cis cavity is resistant to tryptic digestion.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 2.   Limited tryptic digestion of GroEL-alpha beta and SR1-alpha beta complexes in the presence and absence of GroES and nucleotides. GroEL-alpha beta and SR1-alpha beta complexes at 0.8 µg/µl were digested with 20 µg/ml trypsin under specified conditions at 23 °C for 10 min. The reaction was terminated by adding 27 µg/ml trypsin-chymotrypsin inhibitor. Samples were analyzed by SDS-PAGE (upper panel) and Western blotting (lower panel) using a combination of anti-alpha subunit and anti-beta subunit antibodies as a probe.

Under identical conditions, the SR1-alpha beta complex was digested with trypsin in the presence of GroES with or without nucleotides. Only in the presence of GroES and Mg-ATP, where a stable SR1-GroES complex was found (3), was the SR1-bound alpha beta heterodimer resistant to tryptic digestion (Fig. 2, both panels, lane 10). The alpha  and beta  subunits protected from the protease digestion (lane 10) were 89.4 and 101.4% of the starting materials (lane 6), respectively, as measured by densitometry of the Western blot (Fig. 2, lower panel). The results corroborate that 86-kDa alpha beta native-like heterodimer, despite its large size, fits inside the single SR1 cavity encapsulated by GroES, similar to that observed with GroEL.

Unfolded 86-kDa alpha -11-beta Fusion in GroEL and SR1 Cavities Cannot Be Capped by GroES-- Similar protease protection assays were carried out with the complex formed between urea-unfolded alpha -11-beta fusion and GroEL or SR1. Incubation of the urea-denatured alpha -11-beta fusion with GroEL or SR1 produced stable GroEL-alpha -11-beta and SR1-alpha -11-beta complexes, which were isolated as single species by FPLC gel filtration (data not shown). As shown in Fig. 3, the alpha -11-beta fusion bound to GroEL was digested completely as indicated by Coomassie Blue staining, even when both GroES and Mg-ADP were present (lane 4). These conditions facilitate the formation of a stable GroEL-GroES-ADP7 complex. The data indicate that unfolded alpha -11-beta fusion, despite its similar size to the alpha beta heterodimer, cannot be enclosed by GroES inside GroEL cavities. As positive controls, the unfolded alpha -11-beta fusion bound to GroEL was also digested completely when GroES (lane 2) or the nucleotide (lane 3) was absent or when GroES and Mg-ATP were present (lane 5) (Fig. 3). In the same experiment, the unfolded alpha -11-beta bound to the single-ring SR1 was also digested completely by trypsin in the presence of GroES and Mg-ATP (Fig. 3, lane 10). In the presence of Mg-ATP, GroES binds to unoccupied SR1 to form a stable complex. The data indicate that unfolded alpha -11-beta in the SR1 cavity prevents the capping of SR1 by GroES, resulting in degradation of the unfolded alpha -11-beta fusion. The bands under GroEL (lanes 3-5) and SR1 (lanes 8-10) are degradation products of the respective chaperonin (Fig. 3), similar to those shown in Fig. 2. These bands only appear when GroES is present, which is consistent with the finding that interactions between GroEL and GroES result in conformational changes in the former (20).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   Limited tryptic digestion of GroEL-alpha -11-beta and SR1-alpha -11-beta fusion complexes. GroEL-alpha -11-beta and SR1-alpha -11-beta fusion complexes at 0.8 µg/µl were digested under specified conditions as described for Fig. 2. Samples were analyzed by SDS-PAGE followed by Coomassie Blue staining.

Both Subunits of the alpha beta Heterodimer Remain inside the SR1 Cavity Enclosed by GroES-- We have shown previously that in the presence of Mg-ATP, a portion of the alpha beta heterodimer in the GroEL-alpha beta complex undergoes dissociation, resulting in the release of the alpha  subunit into the bulk solvent (15). The SR1-alpha beta preparation showed that only 55% of SR1 cavities were filled with the alpha beta heterodimer (see Fig. 5B). It is possible that in the presence of GroES and Mg-ATP, the alpha beta heterodimer in the SR1-alpha beta complex also dissociates into individual subunits with the released alpha  subunit binding to a new unoccupied SR1 cavity prior to the capping by GroES. In this scenario, the individual SR1-alpha and SR1-beta complexes would present no size constraints for GroES capping and would be protected from tryptic digestion. To rule out this possibility, remaining empty cavities in the SR1-alpha beta preparation were filled by incubation with excess calcium-depleted reduced 14-kDa alpha -lactalbumin that binds to chaperonins with high affinity (21). Fully occupied SR1 cavities were then capped by GroES in the presence of Mg-ATP. After tryptic digestion, the levels of protected alpha  and beta  subunits were determined by SDS-PAGE and Western blotting and quantified by densitometry. Fig. 4 shows that most, if not all, of the alpha  and beta  subunits in the fully occupied SR1-alpha beta -GroES preparation are recovered at the levels of 81 and 83%, respectively, of the amount in the undigested complex. Because all SR1 cavities are occupied, if alpha  and beta  subunits were released into the bulk solution, they would not be able to bind to new SR1 cavities and would therefore be degraded by the protease. The above results exclude the possibility that the heterodimer dissociates into individual alpha  and beta  subunits with the alpha  subunit escaping from the original SR1 cavity prior to capping of the same cavity by GroES.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Recovery of BCKD subunits from the trypsin-digested SR1-alpha beta complex saturated with calcium-free reduced alpha -lactalbumin. The SR1-alpha beta complex was incubated with a large excess amount of calcium-depleted reduced alpha -lactalbumin in the presence of 2 mM dithiothreitol and 0.5 mM EGTA for 10 min at 23 °C. The alpha -lactalbumin-saturated SR1-alpha beta complex preparation was purified on an FPLC Superdex 200 column, followed by tryptic digestion in the presence of GroES and Mg-ATP as described for Fig. 2. The same amount of the SR1-alpha beta complex with trypsin omitted served as a control. Samples were analyzed by Western blotting using anti-alpha antibody or anti-beta antibody, respectively. Densities of the alpha  subunit and the beta  subunit on the same blot were scanned and quantified. The densities of alpha  and beta  subunits without trypsin digestion were set as 100%.

The enclosure of the SR1-alpha beta complex by GroES was deciphered further. As a control, in the absence of Mg-ATP, SR1-beta and excess GroES do not form a complex and migrate separately in HPLC-gel filtration (Fig. 5A, top panel). In the presence of Mg-ATP, a fraction of GroES co-migrates with SR1-beta to produce a stable SR1-beta -GroES complex (Fig. 5A, middle panel). Molar stoichiometry of SR1:beta :GroES in the ternary complex is 1:0.86:0.90 as determined by scanning densitometry (Fig. 5B). The data confirm that Mg-ATP promotes the stable binding of GroES to SR1, without causing the release of the protein substrate. In a parallel experiment, the SR1-alpha beta complex was incubated with excess GroES and Mg-ATP, followed by separation by HPLC-gel filtration. As also shown in Fig. 5A (bottom panel), a stoichiometric amount of GroES binds to SR1-alpha beta complex. The molar ratio of SR1:alpha beta :GroES was estimated to be 1:0.55:1.08 (Fig. 5B). The result indicates that 45% of the SR1 cavity is not occupied by the protein substrate. This was corroborated by the additional binding of calcium-depleted reduced alpha -lactalbumin to the same SR1-alpha beta preparation at a subunit ratio of SR1:alpha -lactalbumin = 1:0.40 (data not shown). The combined data indicate that the alpha beta heterodimer remains inside the same SR1 cavity during the capping of SR1 by GroES and that all of the SR1 cavities including those occupied by the alpha beta heterodimer are encapsulated by GroES.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   HPLC purification and subunit stoichiometry of SR1-beta -GroES and SR1-alpha beta -GroES complexes. A, purification of SR1-beta -GroES and SR1-alpha beta -GroES complexes. SR1-beta (middle panel) and SR1-alpha beta (bottom panel) complexes were incubated with excess amount of GroES and 5 mM Mg-ATP for 5 min at 23 °C and fractionated on an HPLC G3000SWXL gel filtration column in the presence of 0.1 mM Mg-ATP. SR1-beta -GroES- or SR1-alpha beta -GroES-containing fractions were collected and analyzed by SDS-PAGE. As a control, the SR1-beta complex (top panel) was incubated with GroES in the absence of Mg-ATP and separated on HPLC with Mg-ATP omitted from the column buffer. B, the stoichiometry of protein components in the SR1-alpha beta -GroES or the SR1-beta -GroES complex. Subunits of the purified SR1-alpha beta (or -beta )-GroES complex were separated by SDS-PAGE, along with subunit standards on the same gel. After staining with Coomassie Blue, gels were scanned and analyzed by ImageQuant. The amount of each subunit in the SR1-alpha beta (or -beta )-GroES complex was calculated using the standard curve for each polypeptide.

GroEL/GroES-dependent Refolding of Wild-type and alpha -11-beta Fusion BCKD-- Because the single-ring SR1 was unable to refold BCKD proteins, a complete system comprising the double-ring GroEL complex, GroES, and Mg-ATP was utilized in refolding studies. Incubation of the GroEL-alpha beta complex with GroES and Mg-ATP resulted in a recovery of 72% of BCKD activity (Fig. 6A). The activity of BCKD heterotetramer based on the amount of heterodimer present in the GroEL-alpha beta complex was set at 100%. The heterodimeric intermediate does not possess enzyme activity. The renaturation of BCKD activity at 30% with the GroEL-alpha -11-beta fusion complex in the presence of GroES and Mg-ATP was markedly less than that obtained with the GroEL-alpha beta complex. The activity of the active alpha -11-beta homodimer equivalent to the amount of the unfolded monomer in the GroEL-alpha -11-beta fusion complex was set at 100%. Essentially no BCKD activity was recovered with either the GroEL-alpha beta complex or the GroEL-alpha -11-beta fusion complex when Mg-ATP or GroES alone was added to the refolding mixture.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   Chaperonin-mediated recovery of BCKD activity with GroEL-protein intermediate complexes (A) or denatured proteins (B). A, the GroEL-alpha beta or the GroEL-alpha -11-beta complex at 0.8 µM was incubated with 2 µM GroES and 10 mM Mg-ATP at 23 °C for 16 h. BCKD activity was assayed as described previously (14). The activity of BCKD or the alpha -11-beta fusion equivalent to the amount of the alpha beta heterodimer or the unfolded alpha -11-beta fusion in the GroEL-protein complex was set at 100%. B, the refolding of the urea-denatured BCKD and alpha -11-beta fusion was carried out as described previously (13). Wild-type BCKD or the alpha -11-beta fusion protein at 2 mg/ml was denatured in 8 M urea at 23 °C for 1 h, followed by a rapid 100-fold dilution into the refolding mixture containing 1 µM GroEL. Refolding was initiated by adding 2 µM GroES and 10 mM Mg-ATP to the folding mixture. BCKD activity was assayed following incubation at 23 °C for 16 h. Enzyme activity of the same amount of BCKD or the alpha -11-beta fusion protein without denaturation was set at 100%.

Chaperonin-mediated recovery of BCKD activity was also studied using 8 M urea-denatured wild-type BCKD or alpha -11-beta fusion protein, instead of the GroEL-protein complex, as substrate (Fig. 6B). The recovery of BCKD activity with urea-denatured wild-type BCKD was also high at 90% in the presence of GroEL/GroES and Mg-ATP. By comparison, the recovery of BCKD activity at 25% with the urea-denatured alpha -11-beta fusion protein in the presence of GroEL/GroES and Mg-ATP was significantly lower than that with urea-denatured wild-type BCKD. No BCKD activity was recovered from the denatured alpha -11-beta fusion protein when GroES was omitted from the refolding mixture.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The alpha beta heterodimeric intermediate can be isolated from E. coli during expression and assembly of the native BCKD heterotetramer (18). The heterodimer represents an ensemble of trapped energy minima, which in the absence of chaperonins does not dimerize to form the native heterotetramer in vitro (14). We have described previously that the heterodimer does not dissociate into monomers in a measurable equilibrium and binds to GroEL as an intact species with an apparent dissociation constant (KD) of 1.1 × 10-7 M (15). The 86-kDa heterodimeric intermediate bound to GroEL was shown to be partially protected from protease digestion in the presence of Mg-ADP and GroES (15). The data strongly suggest that GroES is capable of capping this large assembly intermediate inside the GroEL cis cavity. In the present study, we extended the investigation by determining the ability of GroES to encapsulate the heterodimeric intermediate inside the GroEL single-ring variant SR1, taking advantage of the absence of the trans ring. Mutations of R452E, E461A, S463A, and V464A in the GroEL equatorial domain prevent the back to back stacking of the two GroEL rings, resulting in the formation of the single-ring complex SR1 (16). The heterodimeric intermediate binds to SR1 to produce a stable SR1-alpha beta complex. In the presence of Mg-ATP, but not Mg-ADP, the SR1-alpha beta complex interacts with GroES, resulting in the existence of a stable SR1-alpha beta -GroES ternary complex. The absence of the trans ring in SR1 confers complete protection of the heterodimer inside the SR1 cavity (Fig. 2). However, it is reasonable to ask whether the heterodimer inside the single SR1 cavity dissociates into individual alpha  and beta  subunits prior to the capping by GroES in the presence of Mg-ATP, followed by the release and rebinding of these individual subunits to different unoccupied chaperonins. In this scenario, new SR1 cavities would harbor the smaller 48.5-kDa alpha  (with the His6 tag) or 37.5-kDa beta  subunit, rather than the larger 86-kDa alpha beta heterodimer, to be capped by GroES. We approached this question by studying the binding of GroES to fully occupied SR1 (Fig. 4). Empty cavities in the preparation of the SR1-alpha beta complex were filled by incubation with an excess amount of reduced and calcium-depleted alpha -lactalbumin (19). The fully occupied SR1 preparation was encapsulated by GroES in the presence of Mg-ATP. The close to complete recovery of both alpha  and beta  subunits at 1:1 stoichiometry following the tryptic digestion strongly supports the notion that both subunits of the alpha beta heterodimer remain inside the original SR1 cavity when the latter is capped by GroES. The equal molar ratio of SR1:GroES in the SR1-alpha beta -GroES ternary complex indicates further that the heterodimer in the SR1-alpha beta complex is enclosed uniformly by GroES (Fig. 5B). Thus, our data validate the encapsulation of the large heterodimeric intermediate inside GroEL and SR1 cavities by GroES. The 86-kDa heterodimer represents the largest partially folded intermediate that is known to be capped by GroES inside the chaperonin cavity.

The crystal structure of GroEL-GroES-ADP7 complex shows a 2-fold enlargement of the cis cavity over the trans to a volume of 175,000 Å3 (20). This volume theoretically is capable of accommodating a globular protein of ~142 kDa beneath GroES, assuming a perfect fit to the actual folded protein volume (20). Nonetheless, the upper limit for an unfolded protein to be encapsulated inside the GroEL cavity by GroES has been shown to be 57 kDa in both in vitro (6) and in vivo (4, 5) studies. This size constraint of 57 kDa for an unfolded protein may reflect that an unfolded polypeptide is more extended than the fully folded protein of similar size. As a result, the space larger than the actual protein volume is needed for an unfolded protein inside the cis cavity to be encapsulated by GroES. As a case in point, we show that the urea-denatured 86-kDa alpha -11-beta fusion cannot be capped by GroES inside GroEL and SR1 cavity, which is consistent with the above size limit for unfolded proteins. Capping of the native-like 86-kDa alpha -11-beta monomeric intermediate has not been studied, because this species cannot be isolated. On the other hand, the alpha beta heterodimeric assembly intermediate with a size similar to the alpha -11-beta fusion possesses a native-like conformation as indicated by ANS fluorescence analysis. The three-dimensional structure of the heterodimeric intermediate has not been determined. Based on the recently solved crystal structure of the native human BCKD heterotetramer, the heterodimeric intermediate contains folded alpha /beta domains in both alpha  and beta  subunits (22). In each subunit, the central beta  sheet is buried by outer alpha  helices in various orientations. Proteins with this kind of folded conformation have been shown to be dependent on chaperonin for proper folding (5). The estimated volume of 132,800 Å3 for the heterodimeric intermediate enables it to fit completely inside the GroEL cis cavity, so as to be encapsulated by GroES as illustrated by simulated packing (Fig. 7).


View larger version (94K):
[in this window]
[in a new window]
 
Fig. 7.   Simulated encapsulation of the 86-kDa alpha beta heterodimer inside the cis GroEL cavity by GroES. The ribbon representation of the GroEL-GroES-ADP7 complex was derived from PDB coordinates (accession number 1AON) with GroEL in green and GroES in yellow. The 86-kDa alpha beta heterodimer representation, with the alpha  subunit in red and the beta  subunit in blue, was derived from PDB coordinates (accession number 1DTW). The graphics were created using Swiss-PDB Viewer and POV-ray.

Volume changes upon protein unfolding may also explain the striking difference between the SR1-alpha beta and the SR1-alpha -11-beta complexes with respect to their ability to be capped by GroES. The partial specific volume change Delta nu ° accompanying protein denaturation can be expressed as a sum of three terms, Delta nu ° = Delta nu V + Delta nu T + Delta nu I, where Delta nu V represents changes due to the loss of intramolecular voids; Delta nu T represents changes in thermal volume, which result from thermally induced mutual molecular vibrations between the unfolded protein and the solvent; and Delta nu I is the interaction volume that represents changes in the solvent volume resulting from interactions of water molecules with charged and polar groups of the unfolded protein (23). The terms Delta nu V and Delta nu I are inherently negative upon protein unfolding, whereas Delta nu T is a positive term associated with the increase in the accessible surface area of the unfolded protein. For a protein of 70 kDa in size, the complete unfolding results in a 30% increase in the partial specific volume mainly because of the positive change in the thermal volume, Delta nu T (23). It is predicted that the larger the protein, the greater increase in the partial specific volume of the unfolded state. Chemical denaturant-induced unfolding such as urea denaturation may still result in measurable residual structures (24). However, it is reasonable to expect a significant increase in the specific volume of the urea-denatured 86-kDa alpha -11-beta fusion protein compared with its folded counterpart, i.e. the native-like alpha beta heterodimer of similar size and essentially identical sequences. The enlarged volume, along with the extended structure, may account for the inability of the unfolded alpha -11-beta fusion to be enclosed by GroES inside the SR1 or GroEL cavity.

We have shown previously that chaperonins GroEL/GroES and Mg-ATP promote dissociation/reassociation cycles of the trapped heterodimeric intermediate to facilitate its conversion to the functional heterotetramer (14, 15). The encapsulation of the heterodimeric intermediate suggests strongly that the unfolding and dissociation of the heterodimer into individual alpha  and beta  subunits occurs inside the encapsulated GroEL cis cavity. The subsequent binding of Mg-ATP to the open trans ring triggers the collapse of the cis assembly. The individual alpha  and beta  subunits released into the bulk solvent reassemble to produce new heterodimeric intermediates with a fraction capable of dimerizing into the native heterotetramer. The dissociation/reassociation cycle perpetuates until all the trapped heterodimeric intermediates are converted to heterotetrameric BCKD. The apparent cis folding throughout the BCKD assembly pathway explains the high levels of BCKD activity recovered with either urea-denatured BCKD or the GroEL-alpha beta complex as substrate. By contrast, the failure of GroES to encapsulate the unfolded alpha -11-beta fusion dictates the chaperonin-mediated trans folding of this protein, similar to that described for 86-kDa maltose-binding protein fusion (8) and 82-kDa aconitase (9). The trans folding mechanism may confer, in part, the markedly lower recovery of BCKD activity with the GroEL-alpha -11-beta complex than that using the GroEL-alpha beta complex as the starting material.

    ACKNOWLEDGEMENTS

We thank Arthur Horwich for kindly supplying the SR1 expression plasmid and Max Wynn and Diana Tomchick for help in simulated molecular graphics of the GroEL-alpha beta -GroES complex.

    FOOTNOTES

* This work was supported by Grant DK26758 from the National Institutes of Health and Grant I-1286 from the Welch Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01655.

§ To whom correspondence should be addressed. Tel.: 214-648-2457; Fax: 214-648-8856; E-mail: david.chuang@utsouthwestern.edu.

Published, JBC Papers in Press, November 12, 2002, DOI 10.1074/jbc.M209705200

    ABBREVIATIONS

The abbreviations used are: BCKD, branched-chain alpha -ketoacid dehydrogenase; ANS, 1-anilino-8-naphthalenesulfonate; FPLC, fast protein liquid chromatography; HPLC, high performance liquid chromatography.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sigler, P. B., Xu, Z., Rye, H. S., Burston, S. G., Fenton, W. A., and Horwich, A. L. (1998) Annu. Rev. Biochem. 67, 581-608[CrossRef][Medline] [Order article via Infotrieve]
2. Hartl, F. U. (1996) Nature 381, 571-579[CrossRef][Medline] [Order article via Infotrieve]
3. Weissman, J. S., Hohl, C. M., Kovalenko, O., Kashi, Y., Chen, S., Braig, K., Saibil, H. R., Fenton, W. A., and Horwich, A. L. (1995) Cell 83, 577-587[Medline] [Order article via Infotrieve]
4. Ewalt, K. L., Hendrick, J. P., Houry, W. A., and Hartl, F. U. (1997) Cell 90, 491-500[Medline] [Order article via Infotrieve]
5. Houry, W. A., Frishman, D., Eckerskorn, C., Lottspeich, F., and Hartl, F. U. (1999) Nature 402, 147-154[CrossRef][Medline] [Order article via Infotrieve]
6. Sakikawa, C., Taguchi, H., Makino, Y., and Yoshida, M. (1999) J. Biol. Chem. 274, 21251-21256[Abstract/Free Full Text]
7. Gordon, C. L., Sather, S. K., Casjens, S., and King, J. (1994) J. Biol. Chem. 269, 27941-27951[Abstract/Free Full Text]
8. Huang, Y. S., and Chuang, D. T. (1999) J. Biol. Chem. 274, 10405-10412[Abstract/Free Full Text]
9. Chaudhuri, T. K., Farr, G. W., Fenton, W. A., Rospert, S., and Horwich, A. L. (2001) Cell 107, 235-246[Medline] [Order article via Infotrieve]
10. Grallert, H., Rutkat, K., and Buchner, J. (1998) J. Biol. Chem. 273, 33305-33310[Abstract/Free Full Text]
11. Bhattacharyya, A. M., and Horowitz, P. M. (2002) Biochemistry 41, 422-429[CrossRef][Medline] [Order article via Infotrieve]
12. Wynn, R. M., Davie, J. R., Cox, R. P., and Chuang, D. T. (1992) J. Biol. Chem. 267, 12400-12403[Abstract/Free Full Text]
13. Chuang, J. L., Wynn, R. M., Song, J. L., and Chuang, D. T. (1999) J. Biol. Chem. 274, 10395-10404[Abstract/Free Full Text]
14. Wynn, R. M., Song, J. L., and Chuang, D. T. (2000) J. Biol. Chem. 275, 2786-2794[Abstract/Free Full Text]
15. Song, J. L., Wynn, R. M., and Chuang, D. T. (2000) J. Biol. Chem. 275, 22305-22312[Abstract/Free Full Text]
16. Horwich, A. L., Burston, S. G., Rye, H. S., Weissman, J. S., and Fenton, W. A. (1998) Methods Enzymol. 290, 141-146[Medline] [Order article via Infotrieve]
17. Clark, A. C., Ramanathan, R., and Frieden, C. (1998) Methods Enzymol. 290, 100-118[Medline] [Order article via Infotrieve]
18. Wynn, R. M., Davie, J. R., Chuang, J. L., Cote, C. D., and Chuang, D. T. (1998) J. Biol. Chem. 273, 13110-13118[Abstract/Free Full Text]
19. Burns, D. M., Horn, V., Paluh, J., and Yanofsky, C. (1990) J. Biol. Chem. 265, 2060-2069[Abstract/Free Full Text]
20. Xu, Z., Horwich, A. L., and Sigler, P. B. (1997) Nature 388, 741-750[CrossRef][Medline] [Order article via Infotrieve]
21. Murai, N., Taguchi, H., and Yoshida, M. (1995) J. Biol. Chem. 270, 19957-19963[Abstract/Free Full Text]
22. Ævarsson, A., Chuang, J., Wynn, M., Truley, S., Chuang, D. T., and Hol, W. G. J. (2000) Structure 8, 277-291[CrossRef][Medline] [Order article via Infotrieve]
23. Chalikian, T. V., and Bresiauer, K. J. (1996) Biopolymers 39, 619-626[CrossRef][Medline] [Order article via Infotrieve]
24. Dill, K. A., and Shortle, D. (1991) Annu. Rev. Biochem. 60, 795-825[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.